I am proud to serve as the Hilary Koprowski Professor and Chair of the Department of Cancer Biology. My overall interests span the breadth of the cancer continuum, from fundamental discovery to clinical translation and care delivery and mitigation of cancer disparities.
Within Jefferson, I am also the Enterprise Director of the NCI-designated Kimmel Cancer Center and the Executive Vice President of Oncology Services for Jefferson Health. SKCC is consistently ranked as one of the top cancer centers in the nation by US News & World Report. Recently, SKCC care and research was expanded across the 14 hospital Jefferson Health system, including development of 3 additional regional SKCC Advanced Care Hubs. Nationally, I serve as the President-Elect of the Association of American Cancer Institutes (AACI), was elected to the Board of the American Association for Cancer Research (AACR), and sit on the Board of Scientific Advisors for the National Cancer Institute (NCI).
My laboratory research interests are dedicated to understanding the mechanisms by which hormone receptor and cell cycle deregulation lead to prostate cancer progression and therapeutic bypass. The overall goal of our research is to utilize this information for successful development of precision medicine, to improve therapeutic outcome through rational therapy delivery. Our studies identifying tumor suppressor, cell cycle, DNA repair, and hormone receptor alterations have uncovered new targets for treating advanced disease, have been translated into first-in-man clinical trials, and have contributed significantly to approval for new interventions for metastatic prostate cancer.
- Impact of cell cycle dysregulation on prostate cancer development and progression
- DNA repair-alterations in human cancers
- Hormone signaling in prostate cancer